Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer

Metastasis, the dissemination and growth of neoplastic cells in an organ distinct from that in which they originated, is the most common cause of death in cancer patients. This is particularly true for pancreatic cancers, where most patients are diagnosed with metastatic disease and few show a sustained response to chemotherapy or radiation therapy. Whether the dismal prognosis of patients with pancreatic cancer compared to patients with other types of cancer is a result of late diagnosis or early dissemination of disease to distant organs is not known. Here we rely on data generated by sequencing the genomes of seven pancreatic cancer metastases to evaluate the clonal relationships among primary and metastatic cancers. We find that clonal populations that give rise to distant metastases are represented within the primary carcinoma, but these clones are genetically evolved from the original parental, non-metastatic clone. Thus, genetic heterogeneity of metastases reflects that within the primary carcinoma. A quantitative analysis of the timing of the genetic evolution of pancreatic cancer was performed, indicating at least a decade between the occurrence of the initiating mutation and the birth of the parental, non-metastatic founder cell. At least five more years are required for the acquisition of metastatic ability and patients die an average of two years thereafter. These data provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window of opportunity for early detection to prevent deaths from metastatic disease.

[1]  Robert Blair Vocci Geology , 1882, Nature.

[2]  Dr. Andreas von Deimling Neoplasia , 1997, Laboratory investigation; a journal of technical methods and pathology.

[3]  G. Burch Of clinical data. , 1977, American heart journal.

[4]  B. Bainbridge,et al.  Genetics , 1981, Experientia.

[5]  B. Lord,et al.  Growth Kinetics of Tumours , 1978, British Journal of Cancer.

[6]  K. Sasaki,et al.  Relationship between labeling indices of KI‐67 and brdurd in human malignant tumors , 1988, Cancer.

[7]  Hans-Peter Schertl,et al.  Geochim. cosmochim. acta , 1989 .

[8]  P. Isaacson,et al.  Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.

[9]  N. Tallada,et al.  An Immunohistochemical Study , 1992 .

[10]  S. Matsuno,et al.  The time of occurrence of liver metastasis in carcinoma of the pancreas , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.

[11]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[12]  T. Terada,et al.  Cell proliferative activity in intraductal papillary-mucinous neoplasms and invasive ductal adenocarcinomas of the pancreas: an immunohistochemical study. , 1998, Archives of pathology & laboratory medicine.

[13]  D A Rew,et al.  Cell production rates in human tissues and tumours and their significance. Part 1: an introduction to the techniques of measurement and their limitations. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  D A Rew,et al.  Cell production rates in human tissues and tumours and their significance. Part II: clinical data. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[16]  I. Fidler,et al.  Critical determinants of metastasis. , 2002, Seminars in cancer biology.

[17]  C. Iacobuzio-Donahue,et al.  Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy , 2005, Cancer biology & therapy.

[18]  K. Gunderson,et al.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. , 2006, Genome research.

[19]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[20]  J. Herman,et al.  Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types , 2007, Cancer biology & therapy.

[21]  K. Suda,et al.  Growth process of small pancreatic carcinoma: a case report with imaging observation for 22 months. , 2008, World journal of gastroenterology.

[22]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[23]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[24]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[25]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[26]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[27]  S. Yachida,et al.  The pathology and genetics of metastatic pancreatic cancer. , 2009, Archives of pathology & laboratory medicine.

[28]  Francisco M. De La Vega,et al.  Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.

[29]  P. Deloukas,et al.  Signatures of mutation and selection in the cancer genome , 2010, Nature.

[30]  M. Moore,et al.  Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.